Ryvu Therapeutics SA · GPW:RVU

Ryvu Therapeutics SA — EHA 2023

30 slides from Ryvu Therapeutics SA's conference presentation, Jun 9, 2023

  1. Slide 1: EHA 2023: RVU120 in AML and HR-MDS, MPN Opportunity

    Slide 1: EHA 2023: RVU120 in AML and HR-MDS, MPN Opportunity

    EHA 2023 RVU120 in AML and HR-MDS RVU120 Opportunity in MPNs 09 June 2023

  2. Slide 2: Note on the presentation and forward looking statements

    Slide 2: Note on the presentation and forward looking statements

    Note on the presentation and forward looking statements This document does not constitute a public offering in the meaning of the Regulation (EU) 2017/1129 of the European Parliament and of the Council, or any other offer or invitation to acquire any Company's securities, nor the incentive to submit

  3. Slide 3: Agenda

    Slide 3: Agenda

    AGENDA HENDRIK NOGAI NOEMI ANGELOSANTO Chief Medical Officer Medical Director, Hematology Introduction to RVU120 Safety and Efficacy of RVU120 in AML/HR-MDS RVU120 potential in Myeloproliferative Neoplasms Summary / Q&A TOMASZ RZYMSKI Director of Translational Medicine

  4. Slide 4: RVU120 is a CDK8/19 inhibitor in clinical development

    Slide 4: RVU120 is a CDK8/19 inhibitor in clinical development

    RVU120 is a CDK8/19 inhibitor currently in clinical development to address unmet medical need in hematologic and solid tumors • First-in-class • High selectivity • Easy to formulate • High potency • Low risk of DDI • Orally available RVU120 is highly selective for CDK8/19 4

  5. Slide 5: RVU120 is currently in development in two clinical trials

    Slide 5: RVU120 is currently in development in two clinical trials

    RVU120 is currently in development in two clinical trials 5 5 CONFIDENTIAL

  6. Slide 6: RVU120: Potential across a broad range of cancers

    Slide 6: RVU120: Potential across a broad range of cancers

    RVU120: Potential across a broad range of cancers Blood Cancers & Disorders Solid tumors AML Neuroendocrine Low-risk MDS Breast High-risk MDS MDS/MPN overlap syndrome Sarcoma Myelofibrosis (MF) HCC NHL Colorectal Diamond-Blackfan Anemia Prostate • Signs of clinical activity in AML/HR-MDS • Preclinic

  7. Slide 7: RVU120 Market Potential in Hematological Malignancies

    Slide 7: RVU120 Market Potential in Hematological Malignancies

    RVU120 Market Potential in Hematological Malignancies AML (ACUTE MYELOID LEUKEMIA) MDS (MYELODYSPLASTIC SYNDROME) MF (MYELOFIBROSIS) • The most common, highly • Disease leading to bone marrow • MF is a bone marrow disease aggressive type damage, classified as cancer characterized by JAK mutations; o

  8. Slide 8: Agenda: Safety and Efficacy of RVU120 in AML/HR-MDS

    Slide 8: Agenda: Safety and Efficacy of RVU120 in AML/HR-MDS

    AGENDA Safety and Efficacy of RVU120 in AML/HR-MDS NOEMI ANGELOSANTO Medical Director, Hematology

  9. Slide 9: Phase 1b dose escalation trial in AML/HR-MDS open at 8 sites

    Slide 9: Phase 1b dose escalation trial in AML/HR-MDS open at 8 sites

    The ongoing Phase 1b dose escalation trial in AML/HR-MDS is currently open at 5 Sites in the US and 3 Sites in Poland RVU120 is given: • orally EOD between D1 and D13 • in a 21-day cycle • until disease progression or unacceptable toxicity 9

  10. Slide 10: Clinical Update: 11 of 24 evaluable patients showed clinical benefit

    Slide 10: Clinical Update: 11 of 24 evaluable patients showed clinical benefit

    Clinical Update: 11 of 24 evaluable patients showed clinical benefit Data cut-off: May 25, 2023 • A total of 29 patients have been treated • Median age 71 years • 26 patients had AML and 3 had HR-MDS • Patients relapsed or were refractory to a median of 3 prior lines of therapy underwent transplant

  11. Slide 11: Patients with poor prognostic characteristics demonstrated clinical benefit

    Slide 11: Patients with poor prognostic characteristics demonstrated clinical benefit

    Patients with poor prognostic characteristics demonstrated clinical benefit with RVU120 treatment Signs of clinical benefit were observed in 11 patients • In total, seven patients experienced meaningful BM blast reductions • One patient with AML achieved a Complete Remission • One patient with AML r

  12. Slide 12: BM blast reduction observed in 12 patients

    Slide 12: BM blast reduction observed in 12 patients

    BM blast reduction observed in 12 patients with evidence of clinical benefit confirmed in 7 patients Best BM blast % reduction 300% • A total of 12 patients showed 250% BM blast reduction while on RVU120 treatment 200% Transplant • Seven of them experienced meaningful 150% eligible clinical benefit:

  13. Slide 13: Patient 107-009 with AML and TP53 double-hit achieved durable blast reduction

    Slide 13: Patient 107-009 with AML and TP53 double-hit achieved durable blast reduction

    Patient 107-009 with AML and TP53 double-hit achieved a durable >70% blast reduction PT 107-009 BM blast reduction while on RVU120 100 • AML with TP53 mutation is associated with poor prognosis1 80 pt 107-009 • When TP53 gene mutation and/or deletion involves BM blasts [%] last study drug administra

  14. Slide 14: Reduction of blasts in patient 106-007 allowed transplant

    Slide 14: Reduction of blasts in patient 106-007 allowed transplant

    Reduction of blasts in patient 106-007 allowed an allogeneic stem cell transplant with potential for long term benefit PT 106-007 BM blast reduction while on RVU120 100 • AML with myelodysplasia 80 • Patient was refractory to all four prior lines of therapy, including venetoclax B M b la s t s [ % ]

  15. Slide 15: RVU120 differentiation on hematopoietic cells

    Slide 15: RVU120 differentiation on hematopoietic cells

    RVU120 differentiation on hematopoietic cells: 6 patients with evidence of increased erythroid differentiation Pt 106-004 Erythroid and Platelet response Pt 106-004 Enhanced Erythroid differentiation 200 150 150 100 [x 1 0 / L ]H g b [g / d l] 52 50 1 1 .0 1 1 .4 22 PLTS 10 9 .6 9 10 5 1 0 1 13 1 13

  16. Slide 16: RVU120 has a favorable safety profile at doses tested to date

    Slide 16: RVU120 has a favorable safety profile at doses tested to date

    RVU120 has a favorable safety profile at doses tested to date RVU120 (10-135 mg) Most common* Treatment Emergent RVU120 was well tolerated Adverse Events (TEAE) Any grade n of pts (%) Grade 3-5 n of pts (%) at doses between 10 and 135 mg Nausea 19 (61%) 0 Vomiting 10 (32%) 1 (3%) • No DLTs and no st

  17. Slide 17: pSTAT5 inhibition correlates with drug exposure

    Slide 17: pSTAT5 inhibition correlates with drug exposure

    In patients treated in both ongoing RVU120 studies, pSTAT5 inhibition correlates with drug exposure 0 Relevant pharmacodynamic effects were observed in both trials -20 % change pSTAT5 • STAT5 is a direct target of CDK8 vs baseline -40 • A decreasing level of pSTAT5 -60 indicates increasing target en

  18. Slide 18: RVU120 is well tolerated and has demonstrated signs of efficacy

    Slide 18: RVU120 is well tolerated and has demonstrated signs of efficacy

    RVU120 is well tolerated and has demonstrated signs of efficacy • Treatment with RVU120 has resulted in clinical benefit in 11 out of 24 patients • RVU120 induces erythropoiesis at a clinically relevant level, which supports further testing of RVU120 in patients with anemia • Available pharmacodynam

  19. Slide 19: Agenda: RVU120 potential in Myeloproliferative Neoplasms

    Slide 19: Agenda: RVU120 potential in Myeloproliferative Neoplasms

    AGENDA RVU120 potential in Myeloproliferative Neoplasms (MPNs) TOMASZ RZYMSKI Director of Translational Medicine

  20. Slide 20: Introduction to Myeloproliferative Neoplasms (MPNs)

    Slide 20: Introduction to Myeloproliferative Neoplasms (MPNs)

    Introduction to Myeloproliferative Neoplasms (MPNs) Pathologic picture of BM myelofibrosis MPNs (MYELOPROLIFERATIVE NEOPLASMS) • MPNs comprise a class of chronic leukemias characterized by abnormal cell growth and fibrotic scars in BM • Three main types: • myelofibrosis (MF) • polycythemia vera (PV)

  21. Slide 21: Confirmed efficacy of RVU120 in myelofibrosis models in vivo

    Slide 21: Confirmed efficacy of RVU120 in myelofibrosis models in vivo

    Confirmed efficacy of RVU120 in myelofibrosis models in vivo Confirmed high efficacy of RVU120 in MF model in vivo 1. Reduction of spleen and liver volume Control 2. Reduction of WBC and PLT overproduction RVU120 20mg/kg BID 3. Change from increased to appropriate number of megakaryocytes RVU120 40m

  22. Slide 22: RVU120 improves over SoC ruxolitinib in myelofibrosis in vivo

    Slide 22: RVU120 improves over SoC ruxolitinib in myelofibrosis in vivo

    RVU120 improves over SoC in myelofibrosis ruxolitinib in vivo JAK2 V617F mut • Ruxolitinib (Jakafi) is a SoC drug that reduces symptoms in MF patients Ruxolitinib-resistant cells • RVU120 is efficacious in JAK mutant cells resistant to ruxolitinib • Confirmed synergy between RVU120 and ruxolitinib i

  23. Slide 23: RVU120 validated as a drug candidate in MPNs/MF

    Slide 23: RVU120 validated as a drug candidate in MPNs/MF

    RVU120 validated as a drug candidate in MPNs/MF Mechanism of RVU120 activity Conclusions in MPNs/MF • RVU120 alone and in combination can reduce symptoms and has disease modifying potential in MPNs/MF • Favorable RVU120 toxicity profile may enable targeting patients non eligible for ruxolitinib trea

  24. Slide 24: Agenda: Summary / Q&A

    Slide 24: Agenda: Summary / Q&A

    AGENDA Summary / Q&A HENDRIK NOGAI Chief Medical Officer

  25. Slide 25: Summary: RVU120 development in AML/HR-MDS and solid tumors

    Slide 25: Summary: RVU120 development in AML/HR-MDS and solid tumors

    Summary: RVU120 development in AML/HR-MDS and solid tumors Phase II initiation planned for H2 2023 Status of dose finding • After the data cut-off for the EHA poster, the 135 mg cohort has been fully enrolled • Enrollment is currently ongoing at 175 mg • 11 of 24 evaluable patients showed clinical b

  26. Slide 26: RVU120 Pipeline-in-a-pill: High market potential

    Slide 26: RVU120 Pipeline-in-a-pill: High market potential

    RVU120 / Pipeline-in-a-pill: High market potential Indication Expansion to a Broad Commercial Space + Other Significant upside in indications such as Solid Tumors prostate cancer and sarcomas +TNBC ~USD 1.3 bn market opportunity (estimated market size in 2029) 4 MF ~USD 2.9 bn USD market opportunity

  27. Slide 27: Broad Clinical Development Plan for RVU120

    Slide 27: Broad Clinical Development Plan for RVU120

    Ryvu is committed to execute a broad Clinical Development Plan for RVU120 HEMATOLOGY CANCERS 2023 2024 2025 2026 2027 2028 US Patient Opportunity 1 I II III IV I II III IV I II III IV I II III IV I II III IV I II III IV I II III IV Fast-to-market strategy: Ph I RVU120 monotherapy 3,400+ Pivotal Ph I

  28. Slide 28: RVU120 Potential further data disclosures in 2023

    Slide 28: RVU120 Potential further data disclosures in 2023

    RVU120 – Potential further data disclosures in 2023 Conference name Date of the Meeting Location ENA 2023 EORTC-NNCI-AACR Symposium Oct 11 to 15 Boston, USA ESMO 2023 Congress of the European Society Oct 20 to 24 Madrid, Spain of Medical Oncology ASH 2023 65th American Society of Hematology Dec 9 to

  29. Slide 29: Q&A

    Slide 29: Q&A

    Q&A RVU120 is tolerated in patients with relapsed or refractory AML/HR-MDS Signs of clinical activity were confirmed in additional patients New translational data support additional opportunity in myeloproliferative neoplasms Transition into Phase 2 development is planned for H2/2023 29

  30. Slide 30: Thank you

    Slide 30: Thank you

    THANK YOU www.ryvu.com ir@ryvu.com 30

Source: Internet Archive copy of ryvu.com

More decks from Ryvu Therapeutics SA

All 21 Ryvu Therapeutics SA decks